CORTESI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.919
AS - Asia 6.701
EU - Europa 5.649
SA - Sud America 1.015
AF - Africa 203
OC - Oceania 45
Continente sconosciuto - Info sul continente non disponibili 10
Totale 28.542
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.589
SG - Singapore 2.021
IT - Italia 1.583
CN - Cina 1.538
GB - Regno Unito 1.311
VN - Vietnam 790
HK - Hong Kong 785
BR - Brasile 755
SE - Svezia 547
DE - Germania 543
BD - Bangladesh 410
FI - Finlandia 303
RU - Federazione Russa 285
FR - Francia 244
UA - Ucraina 193
KR - Corea 175
TR - Turchia 166
CA - Canada 162
IN - India 160
ID - Indonesia 149
IE - Irlanda 117
BG - Bulgaria 95
MX - Messico 79
AR - Argentina 78
NL - Olanda 69
JP - Giappone 63
ZA - Sudafrica 62
IQ - Iraq 60
PL - Polonia 55
PK - Pakistan 47
BE - Belgio 44
EC - Ecuador 42
AE - Emirati Arabi Uniti 41
AT - Austria 41
AU - Australia 41
MY - Malesia 41
SA - Arabia Saudita 38
ES - Italia 37
CO - Colombia 36
MA - Marocco 36
VE - Venezuela 29
PH - Filippine 28
UZ - Uzbekistan 27
CL - Cile 26
LT - Lituania 26
EG - Egitto 22
PY - Paraguay 22
IR - Iran 19
KE - Kenya 19
CH - Svizzera 17
RO - Romania 16
TH - Thailandia 16
TN - Tunisia 16
JO - Giordania 15
NP - Nepal 15
GR - Grecia 14
SI - Slovenia 14
CR - Costa Rica 13
TW - Taiwan 13
AZ - Azerbaigian 12
CZ - Repubblica Ceca 12
BZ - Belize 11
DZ - Algeria 11
IL - Israele 11
JM - Giamaica 11
RS - Serbia 11
PE - Perù 10
SY - Repubblica araba siriana 10
DO - Repubblica Dominicana 9
NO - Norvegia 9
AL - Albania 8
BO - Bolivia 8
HU - Ungheria 8
LV - Lettonia 8
PA - Panama 8
TT - Trinidad e Tobago 8
GE - Georgia 7
UY - Uruguay 7
BY - Bielorussia 6
HN - Honduras 6
LB - Libano 6
PT - Portogallo 6
GT - Guatemala 5
KZ - Kazakistan 5
NI - Nicaragua 5
OM - Oman 5
PS - Palestinian Territory 5
SV - El Salvador 5
AO - Angola 4
DK - Danimarca 4
EE - Estonia 4
ET - Etiopia 4
EU - Europa 4
HR - Croazia 4
KG - Kirghizistan 4
MD - Moldavia 4
MK - Macedonia 4
SN - Senegal 4
AM - Armenia 3
BB - Barbados 3
Totale 28.477
Salva come PNG Salva come JPEG
Città #
Ashburn 1.723
Fairfield 1.333
Santa Clara 1.267
Singapore 1.205
San Jose 784
Hong Kong 766
Woodbridge 737
Southend 721
Chandler 693
Houston 592
Seattle 536
Council Bluffs 495
Cambridge 473
Wilmington 434
Hefei 432
Beijing 322
Nyköping 313
Ann Arbor 300
Dearborn 297
London 284
Los Angeles 284
Jacksonville 283
New York 240
Ho Chi Minh City 239
Helsinki 221
Chicago 213
Milan 196
Hanoi 181
Modena 166
Seoul 159
The Dalles 154
Dallas 144
San Diego 133
Jakarta 116
Dublin 114
Lauterbourg 111
Princeton 99
Sofia 92
Salt Lake City 88
Izmir 87
Moscow 82
Munich 76
Buffalo 74
Bologna 71
Rome 70
Boardman 68
Eugene 67
São Paulo 67
Shanghai 66
Bremen 62
Orem 59
Frankfurt am Main 52
Tokyo 52
Columbus 45
Phoenix 43
Elk Grove Village 41
Haiphong 38
Montreal 38
Dong Ket 37
Warsaw 37
Miano 36
Atlanta 35
Brooklyn 34
Redwood City 33
Da Nang 32
Toronto 32
Chennai 30
Florence 30
Brussels 29
Johannesburg 29
Mexico City 29
Falls Church 28
Miami 27
Denver 26
Belo Horizonte 25
Fremont 25
Turku 25
Reading 24
Tampa 24
Vienna 23
Amsterdam 22
Des Moines 22
Sterling 22
Stockholm 22
Nuremberg 21
Reggio Emilia 21
Guangzhou 20
Las Vegas 20
Philadelphia 20
Tashkent 20
Baghdad 19
Kent 19
Ottawa 19
Rio de Janeiro 19
Brasília 18
Manchester 18
Naples 18
Norwalk 18
Parma 18
Portsmouth 18
Totale 19.142
Salva come PNG Salva come JPEG
Nome #
The italian multi-center project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk 570
A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive italian women 485
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 403
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 398
Prognosis and treatment of micrometastatic breast cancer sentinel lymph node: a population-based study. 393
Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations 392
Identification of protein clusters predictive of response to chemotherapy in breast cancer patients 391
Protein expression patterns associated with advanced stage ovarian cancer 376
Elongation factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility 370
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 366
Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience 365
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 364
Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat 359
A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region 355
Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors 354
Italian family with two independent mutations:3358T/A in BRCA1 and 8756delA in BRCA2 genes. 350
Molecular mechanisms of PARP inhibitors In BRCA-related ovarian cancer 337
Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. 329
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 325
CHIRURGIA PROFILATTICA DELLA MAMMELLA NELLE PAZIENTI PORTATRICI DI MUTAZIONE DEL GENE BRCA 1/2. PERCORSO DIAGNOSTICO-TERAPEUTICO. 318
Prophylactic Surgery to Reduce the Risk of Developing Breast Cancer: Issues and Clinical Implications 309
MRI in high risk women: benefits and problems 307
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 306
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 302
Identification of families with hereditary breast and ovarian cancer for clinical and mammographic surveillance: the Modena Study Group proposal 299
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes 299
Usefulness and limitations of comprehensive characterization of mRNA splicing profiles in the definition of the clinical relevance of BRCA1/2 variants of uncertain significance 297
An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancer 295
MRI before initial surgery outside of clinical trials: the real world! 294
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 291
Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study 291
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 288
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 287
Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers 287
Multicenter comparative multimodality surveillance of women at genetic-familial risk for breast cancer (HIBCRIT study): interim results. 284
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor 284
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life 283
A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate 282
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 281
Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation 281
BRCA1 mutations and clinico-pathological features in a sample of italian women with early-onset breast cancer 281
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 280
Prognosis of screen-detected breast cancers: results of a population based study 274
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 273
Distribution of second primari malignancies suggest a bidirectional effect between breast and endometrial cancer. A population-based study 272
Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the modena familial breast and ovarian cancer center (Italy) 269
Increased incidence of breast cancer in postmenopausal women with high body mass index at the modena screening program 268
Comparison between genotype and phenotype identifies a high-risk population carryingBRCA1 mutations 266
A regional population-based hereditary breast cancer screening tool in Italy: First 5-year results 261
Hereditary risk of breast cancer: not only brca 254
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 253
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study 253
Comment on "Cancer genetic counselling' by P.!Mandich et al. (Ann Oncol 2005; 16: 171) 251
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 251
Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on italian women 245
Twenty-years experience with de novo metastatic breast cancer 243
Characterization of new ATM deletion associated with hereditary breast cancer 243
Chemoprevention strategies for high risk women 241
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification 241
Chemoprevention strategies in hereditary breast and ovarian cancer syndromes 239
Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer 238
Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores 238
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 237
Male Bilateral Risk-Reducing Mastectomy: Report of a Case 234
Indications for breast magnetic resonance imaging. Consensus Document "Attualità in Senologia", Florence 2007 231
Usefulness of breast MRI in a patient with genetic risk 229
Radiological screening programs for women at high risk of developing breast cancer 229
Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations 228
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework 227
Prevalence of BRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectable BRCA1 and BRCA2 point mutations 220
Breast ultrasound in high-risk women 219
Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness 217
BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study 217
Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study 216
Exceptional response to lurbinectedin and irinotecan in BRCA-mutated platinum-resistant ovarian cancer patient: a case report 206
Changes in breast cancer incidence and stage distribution in Modena, Italy: the effect of mammographic screening program. 202
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 200
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 200
The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: A prospective cohort, other biomarker controlled, study 195
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis 194
Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk italian 1 study): final results. 194
Obesity in Postmenopausal Breast Cancer Patients: It Is Time to Improve Actions for a Healthier Lifestyle. The Results of a Comparison Between Two Italian Regions With Different “Presumed” Lifestyles 194
Management of PALB2-associated breast cancer: A literature review and case report 193
Personalized Systemic Therapies in Hereditary Cancer Syndromes 189
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 189
Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk 188
Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report 188
The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance 174
DCE-MRI Radiomic analysis in triple negative ductal invasive breast cancer. Comparison between BRCA and not BRCA mutated patients: Preliminary results 171
BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees 170
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores 170
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review 158
Automation of a capture-based NGS workflow: one thousand patients experience in a diagnostic clinical routine framework 157
Breast cancer screening of mutation carriers in the era of COVID-19 pandemic 157
The spectrum of fancm protein truncating variants in European breast cancer cases 155
A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA) 152
Detection of germline variants in 450 breast/ovarian cancer families with a multi‐gene panel including coding and regulatory regions 151
Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy? 146
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. 145
La predisposizione genetica al cancro dell'ovaio. Individuazione e sorveglianza delle donne a rischio 145
Totale 26.368
Salva come PNG Salva come JPEG
Categoria #
all - tutte 117.335
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 117.335
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.007 139 178 223 90 55 129 114 108 227 163 363 218
2022/20232.107 260 277 136 195 237 252 40 181 330 26 81 92
2023/20241.466 88 76 103 141 236 127 177 177 41 44 77 179
2024/20254.905 145 40 110 286 902 711 442 284 551 209 524 701
2025/202610.957 708 337 763 1.050 1.429 628 1.119 488 994 984 1.564 893
2026/2027432 432 0 0 0 0 0 0 0 0 0 0 0
Totale 28.960